|
FibroBiologics, Inc., a clinical-stage biotechnology company, announced the filing of a patent application with the United States Patent Office covering the use of fibroblast cell-based technology in generating three-dimensional haemopoietic organoids that can give rise to immune cells.
The patent details methods of generating three-dimensional organoids capable of giving rise to hematopoietic cells, including precursors, and/or immune cells. This includes cells such as T cells, B cells, NK cells, macrophages, monocytes, neutrophils, platelets, red blood cells, myeloid-derived suppressor cells, mast cells, eosinophils, basophils, dendritic cells, and CAR-T cells.
“This method potentially offers a rapid, cost-effective, and scalable way to produce therapeutic haemopoietic organoids, which can be transplanted into a living organism to generate desired functional immune cells,” commented chief scientific officer of FibroBiologics, Hamid Khoja, Ph.D. “Additionally, the three-dimensional organoids can be ready for immediate transplantation into a subject within three days of culture or cryopreserved for later use.”
“Our ongoing exploration of therapeutic applications using fibroblast cells continues to provide unique opportunities for our platform,” commented founder & CEO of FibroBiologics, Pete O’Heeron. “This patent, if issued, will allow us to pursue the development of a versatile, scalable solution for generating immune cells in vivo that could revolutionize regenerative medicine and cancer immunotherapy.”
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials.
|